BRCA1 and neoplasm: The resulting dilution of truly BRCA1 methylated patient samples (with epigenetic inactivation of this crucial DNA repair gene within the tumor cells) in a large group of false-positive samples might have masked the association between BRCA1 gene methylation and clinical response to PARP inhibitor therapy.